E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of disease recurrence in patients with breast cancer.
Spanish indication: Prevención de recurrencia de la enfermedad en pacientes con cáncer de mama |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005993 |
E.1.2 | Term | Bone metastases |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Objective: To assess the effect of treatment with MK-0822 5 mg once daily on the risk of developing a first bone metastasis (first disease recurrence) compared to placebo
Objective: To assess the effect of treatment with MK-0822 5 mg once daily on disease-free survival compared to placebo
Objective: To assess the effect of treatment with MK-0822 5 mg once daily in a subset of 250 patients on lumbar spine, total hip, femoral neck, trochanter and total body bone mineral density (BMD) compared to placebo
Objective: To assess the tolerability of treatment with MK-0822 5 mg once daily compared to placebo |
|
E.2.2 | Secondary objectives of the trial |
(1) To assess the effect of treatment with MK-0822 5 mg on the risk of developing a first distant metastasis compared to placebo (2) To assess the effect of treatment with MK-0822 5 mg on the risk of death from any cause compared to placebo (3) To assess the effect of treatment with MK-0822 5 mg compared to placebo on time to a first bone metastasis and disease-free survival in subgroups of patients at high risk of developing distant recurrences based on the presence of molecular markers (4) To assess the ability of a combination of molecular markers (such as Celera 14-gene MetaScore or Genomic Health Oncotype DX) to identify a subgroup of breast cancer patients at high risk of developing bone metastases (5) To assess the effect of treatment with MK-0822 5 mg on biochemical markers of bone turnover compared to placebo |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patient is a woman ≥18 years of age on the day of signing the informed consent • Patient has histologically and/or cytologically confirmed primary Stage II or Stage III breast cancer (must be lymph-node positive and/or with a tumor size >2 cm). regardless of HER-2 status. Stage I patients who are HER-2 positive based either on immunohistochemistry or fluorescent in situ hybridization (FISH technique), or who have a positive genetic signature for breast cancer recurrence using the Celera 14-gene MetaScore, or Genomic Health Oncotype DX, or Mammaprint, are also eligible. • If ER-negative breast cancer, patient has been diagnosed up to 2 years prior to study entry (Visit 1)
OR
• If ER-positive breast cancer, patient has been diagnosed up to 5 years prior to study entry (Visit 1) • Patient has undergone antineoplastic surgery and has recovered, and is at least 2 weeks from previous antineoplastic surgery at the time of screening (Visit 1). • Patient has not received adjuvant chemotherapy (e.g., cyclophosphamide, doxorubicin, carboplatin) or has completed adjuvant chemotherapy at least 6 weeks prior to the randomization visit (Visit 2). This inclusion criterion does not include hormone therapy, which is permitted (see inclusion criterion # 7). • Patient is not receiving hormonal therapy OR if patient is receiving hormonal therapy (e.g., leuprolide, tamoxifen, anastrozole) she is on a stable regimen for at least 3 months at the time of screening (Visit 1). If patient is HER2-positive and is receiving trastuzumab treatment, she must be on a stable regimen for at least 1 month at the time of Visit 1. Patients must also remain on this stable regimen between Visit 1 and Visit 2. • Patient has not undergone radiotherapy, OR if patient has undergone radiotherapy, she has recovered and is at least 4 weeks from the previous radiotherapy at the time of screening (Visit 1). |
|
E.4 | Principal exclusion criteria |
• Patient has bone metastases, or has a history of bone metastases: patient must have a negative bone scan obtained during the screening period, or within 1 month prior to the screening visit (Visit 1). All bone scans and associated imaging studies used for eligibility purposes must be adjudicated by the central radiologist before the patient can be randomized at Visit 2. • Patient has evidence of other distant metastases (e.g., visceral, soft-tissue, or brain). • Patient has had a prior local or regional recurrence of her breast cancer, or a contralateral tumor. DCIS (ductal carcinoma in-situ), and LCIS (lobular carcinoma in-situ) in either the ipsilateral or contralateral breast are permitted. • Patient has ANY of the following: a) is currently receiving a bisphosphonate (e.g., etidronate, clodronate, tiludronate, pamidronate, alendronate, ibandronate, risedronate, olpadronate, neridronate, zoledronate), or other drug therapy for osteoporosis. b) has been treated with an oral bisphosphonate within the 6 months prior to Visit 1. c) has been treated with an intravenous bisphosphonate within the 12 months prior to Visit 1. • Patient is using any of the following potent inhibitors of CYP3A4 within 2 weeks prior to starting blinded study medication: (a) systemically or vaginally administered azole antifungals such as ketoconazole, fluconazole, itraconazole, miconazole, posaconozole, ravuconazole, and voriconazole; (b) nefazodone; (c) the macrolide antibiotics clarithromycin, dirithromycin, erythromycin, and troleandomycin, however, azithromycin, is permitted. The use of any other macrolide antibiotic requires approval by the SPONSOR’s clinical representative. Patients who discontinue these medications at least two weeks prior to starting blinded study medication are eligible. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Bone Metastases Disease Free Survival events |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When the required number of primary endpoints has accrued. This is an event driven trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |